MetaCap

Immunocore Holdings plc ADR (IMCR)

NASDAQ: IMCRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

26.41-0.22 (-0.83%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMCR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.64
52-week range
25.61 – 40.72
Day range
25.61 – 26.77
Volume / Avg
546.18K / 450.88K
Beta
—

52-week range

$25.61$40.72

IMCR stock today

Shares of Immunocore (IMCR) finished lower on Nov 20 at $26.41, a drop of 0.83% or $0.22 per share, versus the S&P 500's 3.70% decline. Shares are 35.1% below their 52-week high of $40.72, set on Dec 5, 2025 and 3.1% above the 52-week low of $25.61, near the bottom of the past year's range. IMCR is down 23.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 32.9%.

Immunocore has posted a net loss over the last twelve months (EPS of -$0.64), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Immunocore

Company profile

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Bahija Jallal Ph.D.
Headquarters
Abingdon
Employees
524
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Immunocore generated $400.0 million in revenue, up 29.0% from fiscal 2024, its 4th consecutive year of revenue growth. Immunocore reported a net loss of $35.5 million, compared with a loss of $51.1 million a year earlier. Gross margin was 98.7% (down from 99.1%) and operating margin -11.3%.

Immunocore annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$400.02M$310.20M$249.43M$174.36M$36.48M
Growth+28.95%+24.37%+43.05%+377.91%—
Net income$-35.51M$-51.09M$-55.29M$-52.54M$-180.03M
EPS (diluted)$-0.71$-1.02$-1.13$-1.15$-4.24

Analyst forecast

Forecast

Consensus (12 analysts)

buy

Avg. price target

$59.30+124.54%

  • Strong buy 2
  • Buy 6
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $33.00High $84.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 6, 2026
EPS actual vs est.
$-0.28 vs $-0.12
Surprise
-133.33%

IMCR news

All IMCR news

Immunocore peers

Health Care sector
IMCR peer companies
CompanyPrice% ChgMarket capCompare
MESOMesoblast Limited ADR10.89-2.59%$1.41Bvs IMCR
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs IMCR
ALVOAlvotech4.12-3.96%$1.47Bvs IMCR
NVAXNovavax Inc.7.47-3.24%$1.23Bvs IMCR
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs IMCR
TSHATaysha Gene Therapies Inc.3.72-1.33%$1.21Bvs IMCR
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs IMCR
VORVor Biopharma Inc.19.19+3.62%$1.18Bvs IMCR

Indexes, lists and sector

Immunocore stock FAQ

What is Immunocore's stock price today?

IMCR last traded at $26.41 as of Nov 20, 4:00 PM EST, down 0.83% on the day. Prices are delayed at least 15 minutes.

Who is Immunocore's CEO?

Dr. Bahija Jallal Ph.D. is the chief executive officer of Immunocore Holdings plc ADR, which has about 524 employees.

What is the IMCR 52-week high?

The 52-week high for IMCR is $40.72 and the 52-week low is $25.61. The stock is currently 35.1% below its high.

Compare IMCR